These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3317364)

  • 1. Specifications and quality control of a yeast-derived hepatitis B vaccine.
    Peetermans JH
    Postgrad Med J; 1987; 63 Suppl 2():97-100. PubMed ID: 3317364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of yeast-derived hepatitis B vaccines in young adults.
    Bergamini F; Zanetti A
    Postgrad Med J; 1987; 63 Suppl 2():137-8. PubMed ID: 3317349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of a new recombinant DNA hepatitis B vaccine.
    Safary A; André F
    Postgrad Med J; 1987; 63 Suppl 2():105-7. PubMed ID: 3317343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a hepatitis B vaccine from transformed yeast cells.
    Pêtre J; Van Wijnendaele F; De Neys B; Conrath K; Van Opstal O; Hauser P; Rutgers T; Cabezon T; Capiau C; Harford N
    Postgrad Med J; 1987; 63 Suppl 2():73-81. PubMed ID: 3317362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The protection of chimpanzees against hepatitis B viral infection using a recombinant yeast-derived hepatitis B surface antigen.
    Schellekens H; de Reus A; Peetermans JH; van Eerd PA
    Postgrad Med J; 1987; 63 Suppl 2():93-6. PubMed ID: 3317363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine.
    André FE; Safary A
    Postgrad Med J; 1987; 63 Suppl 2():169-77. PubMed ID: 3317357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B vaccines prepared from yeast by recombinant DNA techniques: memorandum from a WHO meeting.
    Bull World Health Organ; 1985; 63(1):57-61. PubMed ID: 3886186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between in vitro potency tests for Cuban hepatitis B vaccine: contribution to the standardization process.
    Cuervo ML; de Castro Yanes AF
    Biologicals; 2004 Dec; 32(4):171-6. PubMed ID: 15572098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant yeast-derived hepatitis B vaccine: the prototype for biotechnologically derived old vaccines.
    Ellis RW
    Bioprocess Technol; 1991; 13():355-69. PubMed ID: 1368626
    [No Abstract]   [Full Text] [Related]  

  • 10. Human hepatitis B vaccine from recombinant yeast. 1984.
    McAleer WJ; Buynak EB; Maigetter RZ; Wampler DE; Miller WJ; Hilleman MR
    Biotechnology; 1992; 24():500-2. PubMed ID: 1422061
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality assessment of DNA vaccines: hepatitis-B vaccine.
    Peetermans JH
    J Pharm Biomed Anal; 1989; 7(2):227-32. PubMed ID: 2535120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine.
    Young MD; Schneider DL; Zuckerman AJ; Du W; Dickson B; Maddrey WC;
    Hepatology; 2001 Aug; 34(2):372-6. PubMed ID: 11481622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant yeast hepatitis B vaccine.
    Hilleman MR
    Dev Biol Stand; 1986; 63():57-62. PubMed ID: 3527821
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful development of recombinant DNA-derived pharmaceuticals.
    Werner RG; Pommer CH
    Arzneimittelforschung; 1990 Nov; 40(11):1274-83. PubMed ID: 2085342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
    Raz R; Koren R; Bass D
    Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Release potency tests of hepatitis vaccines.
    Descamps J; Mary A; Rommel E; Anhoury ML; De Neys R; Duchêne M
    Dev Biol Stand; 1999; 101():289-94. PubMed ID: 10566803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality control of biologicals produced by recombinant DNA techniques. WHO consultation.
    WHO Consultation
    Bull World Health Organ; 1983; 61(6):897-911. PubMed ID: 6609009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application of exponent curve model to study the hepatitis B DNA recombinant yeast derived vaccine antibody levels].
    Luo FJ; Dong CM; Shen YG; Huang CJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Sep; 25(9):805-7. PubMed ID: 15555366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The control of biological medicinal products produced by recombinant DNA technology.
    Griffiths E
    Dev Biol Stand; 1985; 59():155-9. PubMed ID: 4007273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to hepatitis B vaccination in high risk population.
    Prakash C; Bhatia R; Kumari S; Verghese T; Datta KK
    J Commun Dis; 2000 Mar; 32(1):17-21. PubMed ID: 11129560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.